A Phase 4 interventional study of Spirometry, PEF measurements and diary cards to evaluate control of Asthma in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-13.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies, regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed, or maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed.
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies. No therapy intervention is made with existing prescribed medications (SERETIDE or SYMBICORT), but evaluations outside standard care is made by evluations with diary cards, questionnaires, PEF evaluations and spirometry which is regarded as the intervention by the Swedish Authorities.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 56 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
Other: Spirometry, PEF measurements and diary cards to evaluate control of Asthma
Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
Other: Spirometry, PEF measurements and diary cards to evaluate control of Asthma
No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
asthma control based on GINA guidelines from 2007.
Time frame: 3 months
Quality of Life, Health economics and exacerbations
Time frame: 3 months
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline